Publication
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugErdafitinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38603651
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification1 | ||||||||
| Erdafitinib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12469Fibroblast Growth Factor Receptor 1 (FGFR1) amplification is frequently observed in estrogen receptor-positive (ER+) breast cancer and is associated with poor prognosis and resistance to endocrine the… (full text at CIViC) PMID 38603651 · Gong et al., 2024 · Open in CIViC | civic |
| FGFR1 Amplification + FGFR2 Amplification + FGFR3 Amplification + FGFR4 AmplificationFGFR1FGFR2FGFR3FGFR41 | ||||||||
| Erdafitinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID12024In this phase II trial, 35 patients harbouring tumours with FGFR1-4 amplifications were treated with FGFR1-4 inhibitor, erdafitinib. 33 of the 35 patients were eligible and treated, while biopsies wer… (full text at CIViC) PMID 38603651 · Gong et al., 2024 · Open in CIViC | civic |